Search Results - "Dochy, E."

Regorafenib dose escalations in the prospective, observational CORRELATE study in patients with metastatic colorectal cancer by Ducreux, M., O’Connor, J., Dochy, E., Fiala-Buskies, S., Cervantes, A., Falcone, A.

Get full text

Exploration of alternative regorafenib regimens to manage hand-foot-skin-reaction by Ploeger, B., Hoefman, S., Ruppert, M., Vis, P., Zisowsky, J., Grothey, A., Van Cutsem, E., Dochy, E., Cleton, A.

Get full text

Real-world dosing of regorafenib (REG) in metastatic colorectal cancer (mCRC): Final results from the prospective, observational CORRELATE study by O'Connor, J M, Ducreux, M, Petersen, L N, Öhler, L, Bergamo, F, Metges, J-P, de Groot, J W, Wang, J-Y, García Paredes, B, Dochy, E, Fiala-Buskies, S, Cervantes, A, Falcone, A

Get full text

406 Aflibercept (Zaltrap) directly attenuates the migration and invasion of colorectal cancer cells by Bouygues, A, Mésange, P, Ayadi, M, Poindessous, V, Chiron, M, Dochy, E, André, T, de Gramont, A, Larsen, A.K

Get full text

PD-029Regorafenib dose escalations in the prospective, observational CORRELATE study in patients with metastatic colorectal cancer by Ducreux, M, O’Connor, J, Dochy, E, Fiala-Buskies, S, Cervantes, A, Falcone, A

Get full text

SO-20 Stanniocalcin 1 (STC1) in patients with refractory colorectal cancer (CRC) treated with regorafenib: An exploratory analysis of the CORRECT trial by Vienot, A., Vernerey, D., Bouard, A., Klajer, E., Asgarov, K., Kim, S., Tournigand, C., Louvet, C., André, T., Rousseau, B., Wespiser, M., Wang, Y., Schulz, A., Dochy, E., Borg, C.

Get full text

P-327Exploration of alternative regorafenib regimens to manage hand-foot-skin-reaction by Ploeger, B, Hoefman, S, Ruppert, M, Vis, P, Zisowsky, J, Grothey, A, Van Cutsem, E, Dochy, E, Cleton, A

Get full text

658PExploration of efficacious alternative regorafenib regimens to manage hand-foot-skin-reaction (HFSR) by Grothey, A, Hoefman, S, Ruppert, M, Vis, P, Zisowsky, J, Fiala-Buskies, S, Van Cutsem, E, Dochy, E, Cleton, A, Ploeger, B A

“…Abstract Background Regorafenib 160 mg/day 3 weeks on/1 week off (1 cycle) significantly improved overall survival (OS) in patients with refractory metastatic…”
Get full text

Exploration of efficacious alternative regorafenib regimens to manage hand-foot-skin-reaction (HFSR) by Grothey, A., Hoefman, S., Ruppert, M., Vis, P., Zisowsky, J., Fiala-Buskies, S., Van Cutsem, E., Dochy, E., Cleton, A., Ploeger, B.A.

Get full text

658P - Exploration of efficacious alternative regorafenib regimens to manage hand-foot-skin-reaction (HFSR) by Grothey, A., Hoefman, S., Ruppert, M., Vis, P., Zisowsky, J., Fiala-Buskies, S., Van Cutsem, E., Dochy, E., Cleton, A., Ploeger, B.A.

“…Regorafenib 160mg/day 3 weeks on/1 week off (1 cycle) significantly improved overall survival (OS) in patients with refractory metastatic colorectal cancer…”
Get full text

Influence of HIF-2alpha deregulation and overexpression of VEGF ligands on the response to aflibercept: Identification of predictive biomarkers by Larsen, A.K., Thouroude, S., Louadj, L., Sabbah, M., Dochy, E., de Gramont, A., Denis, J.A., Bouygues, A.

Get full text

463PReal-world dosing of regorafenib (REG) in metastatic colorectal cancer (mCRC): Final results from the prospective, observational CORRELATE study by O'Connor, J M, Ducreux, M, Petersen, L N, Öhler, L, Bergamo, F, Metges, J-P, de Groot, J W, Wang, J-Y, García Paredes, B, Dochy, E, Fiala-Buskies, S, Cervantes, A, Falcone, A

Get full text

Unanswered questions in prostate cancer — findings of an international multi-stakeholder consensus by the PIONEER consortium by Omar, Muhammad Imran, MacLennan, Steven, Ribal, Maria J., Roobol, Monique J., Dimitropoulos, Konstantinos, van den Broeck, Thomas, MacLennan, Sara J., Axelsson, Susan Evans, Gandaglia, Giorgio, Willemse, Peter-Paul, Mastris, Ken, Ransohoff, John Butler, Devecseri, Zsuzsanna, Abbott, Thomas, De Meulder, Bertrand, Bjartell, Anders, Asiimwe, Alex, N’Dow, James

“…PIONEER is a European network of excellence for big data in prostate cancer consisting of 37 private and public stakeholders from 9 countries across Europe…”
Get full text

P-221 Acquired 5-FU resistance in CRC models is accompanied by upregulation of VEGF-VEGFR1 signaling, increased migration and invasion that can be attenuated by aflibercept by Bouygues, A., Mesange, P., Ayadi, M., Chiron, M., Dochy, E., Andre, T., de Gramont, A., Larsen, A.

Get full text

529PQUALITY OF LIFE (QOL) ON THE AFLIBERCEPT/FOLFIRI REGIMEN: 4TH INTERIM ANALYSIS OF THE GLOBAL AFLIBERCEPT SAFETY AND HEALTH-RELATED QOL PROGRAM by Taieb, J., Bordonaro, R., Bencardino, K., Ciuffreda, L., Di Costanzo, F., Di Bartolomeo, M., Thomas, A.L., Kröning, H., Alfonso, P. García, Borg, C., Moore, Y., Brette, S., Zilocchi, C., Joulain, F., Naoshy, S., Garreau-Laporte, P., Dochy, E., Lledo, G., Sobrero, A.

“…Abstract Aim: In the phase 3 VELOUR trial, aflibercept (ziv-aflibercept in the United States) + FOLFIRI significantly improved overall survival vs FOLFIRI…”
Get full text

Quality of Life (Qol) on the Aflibercept/Folfiri Regimen: 4Th Interim Analysis of the Global Aflibercept Safety and Health-Related Qol Program by Taieb, J., Bordonaro, R., Bencardino, K., Ciuffreda, L., Di Costanzo, F., Di Bartolomeo, M., Thomas, A.L., Kröning, H., Alfonso, P. García, Borg, C., Moore, Y., Brette, S., Zilocchi, C., Joulain, F., Naoshy, S., Garreau-Laporte, P., Dochy, E., Lledo, G., Sobrero, A.

Get full text

Biomarkers ER, PR, HER-2 En Topoisomerase II alpha in Correlation with Response to Neoadjuvant Chemotherapy for Primary Breast Cancer by Lambein, K., Pauwels, P., Buijsrogge, M., Denys, H., Van den Broecke, R., Depypere, H., Van Belle, S., Dochy, E., Cocquyt, V.

“…Abstract Background: Neoadjuvant chemotherapy (CT) is widely accepted for patients with primary breast cancer (BC) not eligible for breast conservative surgery…”
Get full text

News in the medical treatment of breast cancer by Piccart, Martine, Dochy, Emmanuelle, Cardoso, Fatima

“…During the last decade, except for breast cancer, few "solid" tumours have benefited from significant progress in systemic treatment able to reduce the…”
Get full text